Protocols
15 protocol(s) meet the specified criteria
PI: Shea, Thomas
Protocol No.TitleStatus
201312100A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell TransplantOpen
BMT-CTN-0702LTContinued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702 Open
BMT-CTN-1102A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
BMT-CTN-1301A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host DiseaseOpen
BMT-CTN-1302Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple MyelomaOpen
CALGB10603A Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (Pkc412) (Ind #101261) Or Placebo In Newly Diagnosed Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)Open (affiliates only)
CALGB50803A Phase II Trial of Lenalidomide (Revlimid™, CC-5013)(NSC #703813, IND #70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) Open (affiliates only)
CALGB50904A Randomized Phase II Trial of Ofatumumab and Bendamustine Vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma Open (affiliates only)
E1Z11A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)Open (affiliates only)
LCCC1115A Phase II Trial of Induction Chemotherapy with ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)Open (affiliates only)
LCCC1524-ATLPhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)Open
LCCC1532-ATLPhase Ib/II Study of the Administration of T lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s LymphomaOpen
PCYC-1140-IMA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)Open
S1001A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) Open (affiliates only)
TV44688-ONC-30054A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 &#956;g/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy DonorsOpen